Mirae Asset Global Etfs Holdings Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $56.2 Billion
- Q3 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 19,402 shares of PHAT stock, worth $285,015. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,402
Previous 23,334
16.85%
Holding current value
$285,015
Previous $223,000
0.9%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PHAT
# of Institutions
149Shares Held
65.3MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million12.93% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...